Table 1.
Baseline characteristics of patients with gastric cancer undergoing ESD or gastrectomy (n = 539)
| ESD(n = 262) | Surgery(n = 277) | P-value | ||
|---|---|---|---|---|
| Gender(%) | 0.060 | |||
| Male | 204(77.9) | 234(84.5) | ||
| Female | 58(22.1) | 43(15.5) | ||
| Age(%) | 0.664 | |||
| < 60 y | 151(57.6) | 154(55.6) | ||
| ≥ 60 y | 111(42.4) | 123(44.4) | ||
| ASA(%) | 0.420 | |||
| I | 235(89.7) | 242(87.4) | ||
| II | 27(10.3) | 35(12.6) | ||
| ECOG PS(%) | ||||
| 0 | 210(80.2) | 221(79.8) | ||
| 1 | 52(19.8) | 56(20.2) | ||
| Family history of gastric cancer(%) | 0.151 | |||
| Yes | 34(13.0) | 26(9.4) | ||
| No | 228(87.0) | 251(90.6) | ||
| Tumor location(%) | 0.812 | |||
| Cardia | 53(20.2) | 58(21.0) | ||
| Fundus | 62(23.7) | 67(24.2) | ||
| Body | 97(37.0) | 102(36.8) | ||
| Antrum | 50(19.1) | 50(18.0) | ||
| Tumor size(%) | 0.299 | |||
| < 2 cm | 110(42.0) | 129(46.6) | ||
| ≥ 2 cm | 152(58.0) | 148(53.4) | ||
| Differentiation(%) | 0.678 | |||
| High | 77(29.4) | 86(31.1) | ||
| Moderate | 139(53.0) | 142(51.3) | ||
| Poor | 46(17.6) | 49(17.7) | ||
| Vascular invasion(%) | 0.715 | |||
| No | 178(67.9) | 184(66.4) | ||
| Yes | 84(32.1) | 93(33.6) | ||
| P53(%) | < 0.001 | |||
| No | 155(59.2) | 121(43.7) | ||
| Yes | 107(40.8) | 156(56.3) | ||
| Ki-67(%) | 0.814 | |||
| < 50% | 162(61.8) | 186(67.2) | ||
| ≥ 50% | 100(38.2) | 91(32.8) | ||
| Tumor infiltration(%) | 0.874 | |||
| Mucosa | 97(37.0) | 96(34.7) | ||
| Submucosa SM1 | 165(63.0) | 181(65.3) | ||
| MSI status(%) | 0.139 | |||
| MSS/MSI-low | 237(90.5) | 257(92.8) | ||
| MSI-high | 25(9.5) | 20(7.2) | ||
| Cardiovascular disease | 0.532 | |||
| No | 170(64.9) | 172(62.1) | ||
| Yes | 92(35.1) | 105(37.9) | ||
| Liver disease | 0.369 | |||
| No | 249(95.0) | 258(93.1) | ||
| Yes | 13(5.0) | 19(6.9) | ||
| Renal disease | 0.146 | |||
| No | 254(96.9) | 261(94.2) | ||
| Yes | 8(3.1) | 16(5.8) | ||
| Respiratory disease | 0.568 | |||
| No | 255(97.3) | 272(98.2) | ||
| Yes | 7(2.7) | 5(1.8) | ||
| Diabetes | 0.465 | |||
| No | 227(86.6) | 233(84.1) | ||
| Yes | 35(13.4) | 44(15.9) |
ESD: Endoscopic Submucosal Dissection; ASA: American Society of Anesthesiologists; ECOG: Eastern Cooperative Oncology Group; PS: performance status; MSI: microsatellite instability; MSS: microsatellite stable
TNM stages are according to AJCC 8th edition